Announcement PDF ASX Announcement 15 August 2025 Corrected Change of Director's Interest Notice - Pasquale Rombola Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) refers to the Appendix 3Y – ‘Change of Director's Interest Notice - Pasquale Rombola’ lodged with the ASX on Friday, 15 August 2025. The Company advises that the original Appendix 3Y contained an error in the expiry date of the options issued. The previous announcement incorrectly stated: • 370,000 Ordinary Shares & 50,000 Options exercisable at $0.14 expiring on 29 April 2025 for Rombola Superannuation Pty Ltd <Rombola Super Fund A/C> The correct details are: • 370,000 Ordinary Shares & 50,000 Options exercisable at $0.14 expiring on 13 August 2027 for Rombola Superannuation Pty Ltd <Rombola Super Fund A/C>. An updated Appendix 3Y reflecting the correct expiry date is attached. The Company apologises for any inconvenience caused. This announcement has been authorised for release by the Company Secretary. For further information, please contact: Dr Luke Reid Chief Executive Officer luke.reid@microba.com Investor / Media Relations investor@microba.com https://ir.microba.com/welcome About Microba Life Sciences Limited Microba Life Sciences is a company at the forefront of microbiome diagnostics & therapeutics and are on a mission to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit www.microba.com JOIN MICROBA’S INTERACTIVE INVESTOR HUB For more Company information and to engage with management by asking questions about Microba’s latest announcements and updates, visit ir.microba.com/welcome Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity: Microba Life Sciences Ltd ABN: 82 617 096 652 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Date of last notice Pasquale Rombola 20 November 2024 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Date of change No. of securities held prior to change 1. Indirect 1. Rombola Family Pty Ltd <Rombola Family A/C>. Pasquale Rombola is the sole director and sole shareholder of Rombola Family Pty Ltd and a beneficiary of the Rombola Family Trust 2. Rombola Superannuation Pty Ltd <Rombola Super Fund A/C>. Pasquale Rombola is a director and a shareholder of Rombola Superannuation Pty Ltd and a beneficiary of the Rombola Super Fund. 13 August 2025 1. 5,700,000 Ordinary Shares 2. 270,000 Ordinary Shares + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice Class Ordinary Shares & Options Number acquired 600,000 Ordinary Shares and 300,000 Options with an exercise price of $0.14, expiring on 13 August 2027. Number disposed Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation No. of securities held after change Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback Nil $54,000 1. 6,200,000 Ordinary Shares & 250,000 Options with an exercise price of $0.14, expiring on 13 August 2027. 2. 370,000 Ordinary Shares & 50,000 Options exercisable at $0.14, expiring 13 August 2027. Participation in Microba Placement announced to the ASX on 23 June 2025 Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change N/A N/A N/A N/A No. and class of securities to which N/A interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change Part 3 – +Closed period + See chapter 19 for defined terms. Appendix 3Y Page 2 N/A N/A N/A N/A 01/01/2011 Appendix 3Y Change of Director’s Interest Notice Were the interests in the securities or contracts detailed No above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? If prior written clearance was provided, on what date was N/A this provided? + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3